Cell therapy against transplant rejection
Newly founded biotech company ActiTrexx receives funding of € 3.5 million
04-Mar-2021 -
ActiTrexx GmbH, a new biotech spin-off from the University Medical Center Mainz, Germany, has successfully closed its Series A financing. A consortium led by LBBW Venture Capital GmbH with participation from MediVentures GmbH, High-Tech Gründerfonds (HTGF) and Investitions- und Strukturbank ...
cell therapies
graft versus host disease
organ transplantation
+4